Phage therapy at a turning point: Valencia 2026 to define the next era of antibacterial medicine

Mitochondria-Microbiota Task Force

Facebook

XLinkedInWeChatBlueskyMessageWhatsAppEmail

 

image: 

Join clinicians, scientists, regulators, and industry leaders for two days focused on turning phage therapy into clinical reality — from GMP production and regulatory harmonization to precision medicine and global applications in health, veterinary, food, and industry.

The post-antibiotic era is here. Be part of shaping the response.

Valencia, Spain | June 9–10, 2026

view more 

Credit: @ISM

Targeting Phage Therapy 2026 will convene international leaders to accelerate clinical deployment, highlight innovation, and recognize excellence through the Targeting Phage Therapy Awards.

As antimicrobial resistance continues to challenge modern medicine, bacteriophage therapy is entering a decisive phase. The question is no longer whether phages can kill bacteria. The strategic question is whether the field can now build the clinical, regulatory, industrial, and hospital infrastructure required to make phage therapy a mainstream therapeutic option.

The Targeting Phage Therapy 2026 Congress, taking place in Valencia, Spain, on June 9–10, 2026, will bring together leading scientists, clinicians, microbiologists, engineers, biotech leaders, regulators, hospital teams, start-ups, and innovators to address one central challenge:

How can phage therapy move from promising science to accessible, validated, and deployable medicine?

The 2026 agenda is structured around a clear translational trajectory: from mechanisms and clinical evidence to production, regulation, innovation, implementation, and access.

A Strategic Program: From Science to Clinical and Applied Impact

The first day of the congress will focus on “From Science to Clinical and Applied Impact” It will explore how phage biology, therapeutic design, chronic infection models, engineered phages, and One Health applications can shape the next generation of antibacterial strategies.

The congress will open with Benjamin K. Chan, Yale University, USA, who will deliver the opening keynote lecture: Turning Evolution into Therapy: A New Strategy to Fight Antibiotic-Resistant Infections. His lecture will highlight one of the most powerful shifts in the field: using bacterial evolution not as an obstacle, but as a therapeutic lever. This strategy can potentially drive bacteria toward evolutionary trade-offs, weaken pathogenicity, and restore antibiotic sensitivity.

Other confirmed speakers for Day 1 include:

Opening Keynote Lecture: Turning Evolution into Therapy: A New Strategy to Fight Antibiotic-Resistant Infections
Benjamin K. Chan, Yale University, USA

Advancing Phage Therapy for Chronic Infections: From Experimental Evidence to Clinical Use
Joana Azeredo, University of Minho, Portugal

Bacteriophages Redesigned: Engineering of Next-Generation Phage Therapeutics and Diagnostics
Martin J. Loessner, ETH Zürich, Switzerland

The Human Virome in Chronic Infection: What Patient Phages Teach Us About Therapeutic Phage Design
Katrine Whiteson, UC Irvine, USA

Phage for Sustainable and Scalable Infection Control in Aquaculture
Adelaide Almeida, Universidade de Aveiro, Portugal

Phage Therapy in Livestock Disease Models: Lessons for Animal and Human Health
Robert Atterbury, University of Nottingham, United Kingdom

Nasopharyngeal Phages: The Silent Players in Piglet Health
Oscar Mencía-Ares, Universidad de León, Spain

Day 2: Enablers for Scale, Access, and Impact

The second day will focus on the decisive enablers of phage therapy deployment: production, regulation, quality standards, personalized treatment pathways, manufacturing, hospital integration, and innovation. 

Confirmed speakers for Day 2 include:

Personalized Bacteriophage Therapy in Germany and Beyond – A Consensus-Based Guideline
Annika Y. Classen, Cologne University Hospital, Germany

France launches its first public GMP platform to produce large batches of therapeutic phages at affordable scale
Frédéric Laurent, Hospices Civils de Lyon, France

The Qualified Presumption of Safety (QPS) Qualification of Lytic Bacteriophages: Scientific Criteria and Regulatory Perspectives
Juan Evaristo Suárez, Universidad de Oviedo, Spain

From Bioreactor to Patient: Scalable Manufacturing and Delivery of Therapeutic Phages
Danish J. Malik, Loughborough University, United Kingdom

Chronic Respiratory Infections in the Inflamed Lung: Host–Pathogen Interactions and Opportunities for Phage Therapeutics
Paula Zamora, University of Kansas Medical Center, USA

Personalized Phage Therapy at the Hannover Medical School: barriers, challenges, and next steps
Evgenii Rubalskii, Medizinische Hochschule Hannover, Germany

From Promise to Practice: What Will Make Phage Therapy Mainstream?

This final discussion will address the key barriers that still separate phage therapy from routine medical use: clinical validation, regulatory alignment, GMP production, reimbursement, hospital adoption, and international coordination. 

Submit Your Innovation: From Concept to Clinical Impact

The congress invites start-ups, biotech companies, academic teams, hospitals, diagnostic developers, manufacturing platforms, AI-based phage-matching initiatives, translational consortia, and One Health innovators to submit their innovations.

Selected innovations may be presented during the congress and highlighted to an international audience of experts, clinicians, investors, industry representatives, and institutional partners.

The Targeting Phage Therapy Awards 2026 will be a central highlight of the congress. These awards will recognize outstanding contributions that are helping transform phage therapy from scientific promise into clinical, technological, and societal impact.

The awards will spotlight excellence in five major areas:

• Scientific Excellence Award
  Recognizing outstanding research in phage biology, phage-bacteria interactions, resistance evolution, host range, genomics, therapeutic design, and mechanistic understanding.
• Clinical Translation Award
  Honoring work that brings phage therapy closer to patient care, including clinical case studies, compassionate use programs, hospital implementation, treatment protocols, and multidisciplinary clinical workflows.
• Innovation and Technology Award
  Recognizing novel platforms and technologies that can accelerate phage therapy deployment, including diagnostics, manufacturing, AI, engineering, formulation, delivery systems, and quality control.
• Young Investigator Award
  Supporting the next generation of phage therapy researchers through recognition of outstanding short oral presentations, posters, and early-career contributions.
• One Health Impact Award
  Highlighting work that extends phage applications beyond human medicine, including food safety, aquaculture, livestock, environmental microbiology, and antimicrobial resistance control.

- Short Oral Abstract Submission Deadline: May 9, 2026
- Poster Abstract Submission Deadline: May 13, 2026
- Innovation Submissions: Open

Submit your abstract here: https://phagetherapy-site.com/

Awards and Recognitions: Open for selected scientific, clinical, technological, young investigator, and One Health contributions

The ambition is clear: to move phage therapy from fragmented success stories toward a structured therapeutic ecosystem.

About Targeting Phage Therapy 2026

Targeting Phage Therapy 2026 will take place in Valencia, Spain, on June 9–10, 2026. The congress is dedicated to accelerating the translation of bacteriophage science into clinical, industrial, regulatory, and One Health applications.

Congress: Targeting Phage Therapy 2026
Dates: June 9–10, 2026
Location: Valencia, Spain
Abstracts, innovation submissions and awards: Open
Website: Targeting Phage Therapy 2026 / Agenda at a Glance: www.phagetherapy-site.com

 

Ancient viruses serving as gene delivery couriers to help bacteria resist antibiotics

John Innes Centre

FacebookX

BlueskyMessageWhatsAppEmail

 

image: 

Left: fluorescence microscopy showing C. crescentus bacterial cells producing GTA particles (cells have been engineered to glow green when producing GTAs). Right: cryo-electron microscopy tomogram showing a ‘cross-section’ through a single C. crescentus cell producing GTA particles (magenta and yellow). Bacterial envelope layers are shown in blue, cyan, and green. A nutrient storage granule is visible (grey). Ribosomes (protein factories) are shown in orange.

view more 

Credit: Dr Emma Banks

Research has shed important new light on the enemies-turned-allies that allow bacteria to exchange genes, including those linked to antimicrobial resistance (AMR).   

 

The insights, which expand our understanding of the major global health threat of AMR, came as John Innes Centre researchers investigated the curious phenomena of gene transfer agents (GTAs).   

These gene-carrying particles look like bacteriophages (viruses that infect bacteria), but they have been domesticated from ancient viruses and put to beneficial use under the control of the bacterial host cell.  

Acting as couriers, they take up parcels of host bacterial DNA and deliver them to neighbouring bacteria. This “selfless” sharing, known as horizontal gene transfer, can rapidly spread useful traits including genes that confer resistance to antibiotic drugs used to treat infections. 

A crucial GTA life stage is host cell lysis: the breaking down of a host cell to release DNA-packed GTA particles. Previously, it was unclear how GTA particles escape their host bacterial cells. 

In this study, which appears in Nature Microbiology, the team used a deep sequencing-based screening method to identify genes critical for GTA function in the model bacterium Caulobacter crescentus.  

This identified a three-gene control hub, LypABC, encoding bacterial proteins. When these lypABC genes were deleted, bacteria could no longer lyse to release GTA particles. In contrast, by overexpressing the lypABC hub they obtained a very high proportion of lysing cells. Together, these experiments identified LypABC as a control mechanism for GTA-mediated cell lysis.  

Surprisingly, LypABC resembles a bacterial anti-phage immune system since it contains protein domains which are typically required for defence against viruses. However, this collaborative effort between the John Innes Centre, the University of York, and the Rowland Institute at Harvard, suggests it has been repurposed to release GTA particles for gene transfer.  

They also identified a regulatory protein which is required for strict control of both GTA activation and GTA-mediated lysis. This control is important as misregulation of LypABC is highly toxic to bacterial cells.  

In highlighting the plasticity of bacterial domains, the study advances fundamental knowledge of how gene transfer occurs between bacterial cells and offers an important clue to understanding how AMR occurs.  

First author of the study Dr Emma Banks, a Royal Commission for the Exhibition of 1851 Research Fellow, said: “What’s particularly interesting is that LypABC looks like an immune system, yet bacteria are using it to release GTA particles. It suggests that immune systems can be repurposed to help bacteria share DNA with each other - a process that can contribute to the spread of antibiotic resistance.” 

The next step for the research is to discover how the LypABC control hub is activated and how it functions to control the rupture of bacterial cells and release of GTA particles. 

“A bacterial CARD-NLR-like immune system controls the release of gene transfer agents”, appears in Nature Microbiology.  

 

---

Journal

Nature Microbiology

DOI

10.1038/s41564-026-02316-4 

Method of Research

Experimental study

Subject of Research

Cells

Article Title

A bacterial CARD–NLR-like immune system controls the release of gene transfer agents

Article Publication Date

16-Apr-2026

 

One of cholera’s great enemies is found in the human gut

Wellcome Trust Sanger Institute

Facebook

XLinkedInWeChatBlueskyMessageWhatsAppEmail

Cholera-causing bacteria are locked in an evolutionary arms race with a viral nemesis, according to a new genomic study.

Experts at the Wellcome Sanger Institute, icddr,b (International Centre for Diarrhoeal Disease Research, Bangladesh), the Post Graduate Institute of Medical Education & Research (PGIMER), and their collaborators, found that in the Ganges Delta, cholera bacteria rapidly gain and lose special armour that protects against attacks from the virus, known as bacteriophage ICP1.

The new research, published today (1 April) in Nature, highlighted that maintaining these anti-viral defences leads to lower disease severity of cholera in humans and reduced ability to spread outside the country for this bacterial strain.

By looking at the ecology of cholera in South Asia, this study challenges the long-held belief that the Ganges Delta is the global source of cholera. Knowing more about the strains and the factors that influence the spread of cholera bacteria in different regions could help provide an early warning system, identifying high-risk strains before they escalate and allowing for early intervention.

It could also help develop new treatments, for example, research into whether the virus could be harnessed to help stop cholera in the future.

Cholera is an acute diarrheal infection, which can be fatal within hours if untreated. It is caused by the bacterium, Vibrio cholerae (V. cholerae), which spreads through contaminated food and water1. Globally, we are in the seventh cholera pandemic, which started in 1961, with an estimated 1.3 to 4 million cases and up to 143,000 deaths per year from the condition worldwide1. It has been shown that the seventh pandemic is caused by V. cholerae strain 7PET O1, originating from the Bay of Bengal, which borders Bangladesh and India, and it was thought that the Ganges Delta was the global source of cholera.   

This new research sequenced bacterial samples from across Bangladesh and North India, creating the most comprehensive dataset of cholera in this area to date, containing over 2,300 genomes collected across approximately 20 years. They found that it was the Ganges Basin, not the Ganges Delta, that was the primary global source of cholera in that time.

By tracking the bacterial spread, they also uncovered that the bacteria do not simply follow the flow of rivers. Instead, they tend to stay within national borders, suggesting that human travel and population density are more important for cholera transmission than the natural environment.

They also found V. cholerae in Bangladesh, strain 7PET O1, rapidly gain and lose genetic elements known as defence systems, which act like armour helping them survive against their viral nemesis, the bacteriophage ICP1. Bacteriophages, also known as phages, are natural viruses that attack bacteria. They need bacteria to replicate, are generally not harmful to human cells, can rapidly kill their bacterial host, and are often found in the human gut microbiome.

By analysing cholera data in South Asia spanning 20 years, the team found evidence that the bacteria are constantly fighting off attacks from ICP1 using different armour or shields. In turn, the study shows that the ICP1 virus develops its own ‘anti-defence’ weapons to hack through those shields and continue its attack. While it has been shown previously that the presence of ICP1 in the gut is linked with less severe disease2, as the virus kills off the disease-causing bacteria2, this study shows that there is an evolutionary arms race in Bangladesh between the bacteria and ICP1, with each species developing new ways to defeat the other. This compromises the bacteria's ability to spread out of the country, limiting its ability to spread globally.

In the future, it may be possible to use our understanding of this arms race to develop new treatments or control strategies for cholera.

The study suggests that a better understanding of the natural ecology of this important disease could lead to early warning systems, highlighting V. cholerae bacteria that have lost new types of defensive shields and are more likely to cause severe disease and spread globally to cause epidemics. By identifying these high-risk strains before they spread, authorities could update treatment recommendations, deploy vaccines and improve water sanitation in specific areas to prevent local outbreaks from turning into global pandemics. Overall, by taking an ecological view of the global source of cholera, it is possible to stop the spread of these disease-causing bacteria to other parts of the world.

Dr Amber Barton, co-first author at the Wellcome Sanger Institute, said: “Our research uncovered the evolutionary struggle between cholera bacteria in Bangladesh, and the bacteriophage that preys on them. Specifically, the discovery of rapid loss and gain of V. cholerae’s protective defences and their impact on disease severity is key to understanding the factors involved in the spread of this bacterium. Without the defences, the bacteria are more dangerous to humans, and tracking this in real time, through genomics, can help us identify when the strains pose the highest risk and intervene early. Additionally, future research into cholera and microbiome interactions in other regions of the world could reveal other phages that prey on the bacteria, which may help develop new treatments in the future.”

Dr Firdausi Qadri, co-senior author at the icddr,b in Bangladesh, said: “By creating the most comprehensive genetic database of cholera bacteria samples across Bangladesh and North India, our study has shown that our understanding of the global source of cholera needs updating and refinement to consider a region that spans Bangladesh and India. We can also see that cholera spread does not follow the rivers and waterways. This suggests that, despite cholera being a water-borne pathogen, the role of human travel and population density are bigger factors in cholera transmission than the surrounding environment. Understanding this can help inform public health interventions to help stop the spread of infections.”

Professor Nick Thomson, co-senior author at the Wellcome Sanger Institute, said: “The world is in its seventh global pandemic of cholera, with the bacteria evolving and adapting to treatments and the world around it. By taking an ecological view of cholera across whole regions of the world using genomics, we have been able to dispel previous inaccuracies about the global spread of the pandemic and provide a clearer picture of the factors and threats these bacteria face. This can help inform public health strategies and future treatments to hopefully end this pandemic and protect the many thousands of people impacted.”

ENDS

Notes to Editors:

1. Cholera. World Health Organization. Available at https://www.who.int/news-room/fact-sheets/detail/cholera [accessed March 2026]
2. N. Madi, et al. (2024) 'Phage predation, disease severity, and pathogen genetic diversity in cholera patients.' Science. DOI:10.1126/science.adj3166

Publication:

A. Barton, M. H. Afrad, A. Taylor-Brown, et al. (2026) ‘Evolution of Pandemic Cholera at its Global Source’. Nature. DOI: 10.1038/s41586-026-10340-x

Funding:

This research was part-funded by the Bill and Melinda Gates Foundation and Wellcome.

Selected websites:

The Wellcome Sanger Institute

The Wellcome Sanger Institute is a world leader in genomics research. We apply and explore genomic technologies at scale to advance understanding of biology and improve health. Making discoveries not easily made elsewhere, our research delivers insights across health, disease, evolution and pathogen biology. We are open and collaborative; our data, results, tools, technologies and training are freely shared across the globe to advance science.

Funded by Wellcome, we have the freedom to think long-term and push the boundaries of genomics. We take on the challenges of applying our research to the real world, where we aim to bring benefit to people and society.

Find out more at www.sanger.ac.uk or follow us on Twitter, Instagram, Facebook, LinkedIn and on our Blog.

About Wellcome

Wellcome supports science to solve the urgent health challenges facing everyone. We support discovery research into life, health and wellbeing, and we’re taking on three worldwide health challenges: mental health, infectious disease and climate and health. https://wellcome.org/

---

Journal

Nature

DOI

10.1038/s41586-026-10340-x 

Article Title

Evolution of Pandemic Cholera at its Global Source

Article Publication Date

1-Apr-2026

 

New antibiotic alternative fights foodborne salmonella

American Society for Microbiology

FacebookXLinkedInWeChatBlueskyMessageWhatsAppEmail

Key Points:

• Antimicrobial-resistant Salmonella poses severe challenges to global food safety and public health.
• Biofilms formed by Salmonella on food and food-processing equipment are difficult to eliminate with conventional disinfection methods.
• Researchers have discovered an alternative method using the bacteriophage W5, which specifically targets Salmonella, paving the way for novel phage-based disinfectants.

Washington, D.C.—Researchers from China have identified a novel bacteriophage that offers a highly promising “green” biocontrol solution against foodborne Salmonella. The study was published in Applied and Environmental Microbiology, a journal of the American Society for Microbiology.

This study was conducted to address the severe challenges posed by antimicrobial-resistant Salmonella to global food safety and public health. Conventional disinfection methods often fail to effectively eliminate the stubborn biofilms formed by Salmonella on food and food-processing equipment surfaces, and the overuse of antibiotics has further accelerated the emergence of drug-resistant strains. There is an urgent need to develop novel, targeted and sustainable alternative antibacterial strategies. Bacteriophages, viruses capable of specifically lysing bacteria, offer a highly promising solution.

In the new study, the researchers isolated bacteriophages that target Salmonella from wastewater and selected the most effective one, phage W5, from multiple candidates. The researchers characterized W5's morphology, stability under various conditions, growth kinetics and genomic sequence to confirm its efficacy and safety. They also evaluated W5's ability to reduce Salmonella and disrupt biofilms on foods (milk, meat, eggs) and food-contact surfaces under realistic storage conditions.

“We discovered a safe and highly effective natural virus (bacteriophage W5) that functions like a precision-guided missile, capable of eliminating harmful Salmonella on various foods and packaging materials, showing great potential as a novel guardian for food safety,” said corresponding study author and professor Huitian Gou from the College of Veterinary Medicine, Gansu Agricultural University in Lanzhou, China. “The research demonstrates that W5 can efficiently lyse planktonic bacteria and eradicate biofilms with high specificity. Genomic analysis further confirms its safety profile, as it lacks virulence and antibiotic resistance genes.”

The researchers say the findings establish a solid foundation for developing novel phage-based disinfectants or preservatives, opening an innovative pathway to combat antibiotic resistance and enhance food safety. As a natural biological entity, phage W5 offers a "green" solution for decontamination, aligning with consumer demand for clean-label products and sustainable production methods. It leaves no harmful chemical residues on food or in the environment.

“We firmly believe that phage W5 holds immense potential for seamless integration across the entire from farm to fork supply chain. It can be incorporated into multiple critical stages—for instance, as a feed additive in livestock farming, a surface disinfectant in meat processing plants, or even a preservative spray for fresh produce at the consumption end,” Gou said. “We eagerly look forward to collaborating with industry partners to translate this effective green solution from the laboratory to the market, working together to safeguard food safety.”

###

The American Society for Microbiology is one of the largest professional societies dedicated to the life sciences and is composed of over 38,000 scientists and health practitioners. ASM's mission is to promote and advance the microbial sciences.  

ASM advances the microbial sciences through conferences, publications, certifications, educational opportunities and advocacy efforts. It enhances laboratory capacity around the globe through training and resources. It provides a network for scientists in academia, industry and clinical settings. Additionally, ASM promotes a deeper understanding of the microbial sciences to all audiences.

---

Journal

Applied and Environmental Microbiology

UH OH

With Evo 2, AI can model and design the genetic code for all domains of life

The largest foundation model for biology to date is now published in the journal Nature

Arc Institute

FacebookXLinkedInWeChatBlueskyMessageWhatsAppEmail

 

image: 

This illustration depics how Evo 2 learns the genetic language shared by all living things, from woolly mammoths to bacteria.

view more 

Credit: Arc Institute

The DNA foundation model Evo 2, first released in February 2025 as a preprint, is now published in the journal Nature. Trained on the DNA of over 100,000 species across the entire tree of life, Evo 2 can identify patterns in gene sequences across disparate organisms that experimental researchers would need years to uncover. The machine learning model can accurately identify disease-causing mutations in human genes and is capable of designing new genomes that are as long as the genomes of simple bacteria.

Evo 2 was developed by scientists from Arc Institute and NVIDIA, convening collaborators across Stanford University, UC Berkeley, and UC San Francisco. The model's code is publicly accessible from Arc's GitHub, and is also integrated into the NVIDIA BioNeMo framework, as part of a collaboration between Arc Institute and NVIDIA to accelerate scientific research. Arc Institute also worked with AI research lab Goodfire to develop a mechanistic interpretability visualizer that uncovers the key biological features and patterns the model learns to recognize in genomic sequences. The Evo team has shared its training data, training and inference code, and model weights, making it the largest-scale, fully open source AI model to date.

Building on its predecessor Evo 1, which was trained entirely on single-cell genomes, Evo 2 is the largest artificial intelligence model in biology to date, trained on over 9.3 trillion nucleotides—the building blocks that make up DNA or RNA—from over 128,000 whole genomes as well as metagenomic data. In addition to an expanded collection of bacterial, archaeal, and phage genomes, Evo 2 includes information from humans, plants, and other single-celled and multi-cellular species in the eukaryotic domain of life.

"Our development of Evo 1 and Evo 2 represents a key moment in the emerging field of generative biology, as the models have enabled machines to read, write, and think in the language of nucleotides," says Patrick Hsu, Arc Institute Co-Founder, Arc Core Investigator, an Assistant Professor of Bioengineering and Deb Faculty Fellow at University of California, Berkeley, and a co-senior author on the paper. "Evo 2 has a generalist understanding of the tree of life that's useful for a multitude of tasks, from predicting disease-causing mutations to designing potential code for artificial life. We're excited to see what the research community builds on top of these foundation models."

Evolution has encoded biological information in DNA and RNA, creating patterns that Evo 2 can detect and utilize. "Just as the world has left its imprint on the language of the Internet used to train large language models, evolution has left its imprint on biological sequences," says co-senior author Brian Hie, an Assistant Professor of Chemical Engineering at Stanford University, the Dieter Schwarz Foundation Stanford Data Science Faculty Fellow, and Arc Institute Innovation Investigator in Residence. "These patterns, refined over millions of years, contain signals about how molecules work and interact."

Evo 2 was trained for several months on the NVIDIA DGX Cloud AI platform via AWS, utilizing over 2,000 NVIDIA H100 GPUs and bolstered by collaboration with NVIDIA researchers and engineers. The model can process genetic sequences of up to 1 million nucleotides at once, enabling it to understand relationships between distant parts of a genome. Achieving this technical feat required the research team to reimagine how an AI model could quickly ingest and make inferences about this scale of data. The resulting AI architecture, called StripedHyena 2, enabled Evo 2 to be trained with 30 times more data than Evo 1 and reason over 8 times as many nucleotides at a time.

The model already shows enough versatility to identify genetic changes that affect protein function and organism fitness. For example, in tests with variants of the breast cancer-associated gene BRCA1, Evo 2 achieved over 90% accuracy in predicting which mutations are benign versus potentially pathogenic. Insights like this could save countless hours and research dollars needed to run cell or animal experiments, by finding genetic causes of human diseases and accelerating the development of new medicines.

In the year since its preprint release, researchers have applied the model to a range of scientific problems, from predicting genetic disease risk in Alzheimer's patients to assessing variant effects across domesticated animal species. Arc researchers have also used Evo 2 to design functional synthetic bacteriophages, demonstrating potential applications for treating antibiotic-resistant bacteria.

In addition to genetic analysis, Evo 2 could be useful for engineering new biological tools or treatments. "If you have a gene therapy that you want to turn on only in neurons to avoid side effects, or only in liver cells, you could design a genetic element that is only accessible in those specific cells," says co-author and computational biologist Hani Goodarzi, an Arc Core Investigator and an Associate Professor of Biochemistry and Biophysics at the University of California, San Francisco. "This precise control could help develop more targeted treatments with fewer side effects."

The research team envisions that more specific AI models could be built with Evo 2 as a foundation. "In a loose way, you can think of the model almost like an operating system kernel—you can have all of these different applications that are built on top of it," says Arc's Chief Technology Officer Dave Burke, a co-author on the paper. "From predicting how single DNA mutations affect a protein's function to designing genetic elements that behave differently in different cell types, as we continue to refine the model and researchers begin using it in creative ways, we expect to see beneficial uses for Evo 2 we haven't even imagined yet."

In consideration of potential ethics and safety risks, the scientists excluded pathogens that infect humans and other complex organisms from Evo 2's base data set, and ensured that the model would not return productive answers to queries about these pathogens. Co-author Tina Hernandez-Boussard, a Stanford Professor of Medicine, and her lab members assisted the team to implement responsible development and deployment of this technology.

"Evo 2 has fundamentally advanced our understanding of biological systems," says Anthony Costa, director of digital biology at NVIDIA. "By overcoming previous limitations in the scale of biological foundation models with a unique architecture and the largest integrated dataset of its kind, Evo 2 generalizes across more known biology than any other model to date — and by releasing these capabilities broadly, Arc Institute has given scientists around the world a new partner in solving humanity's most pressing health and disease challenges."

###

Brixi, G., Durrant, M.G., Ku, J., Naghipourfar, M., Poli, M., Brockman, G., Chang, D., Fanton, A., Gonzalez, G.A., King, S.H., Li, D.B., Merchant, A.T., Nguyen, E., Ricci-Tam, C., Romero, D.W., Schmok, J.C., Sun, G., Taghibakhshi, A., Vorontsov, A., Yang, B., Deng, M., Gorton, L., Nguyen, N., Wang, N.K., Pearce, M.T., Simon, E., Adams, E., Amador, Z.J., Ashley, E.A., Baccus, S.A., Dai, H., Dillmann, S., Ermon, S., Guo, D., Herschl, M.H., Ilango, R., Janik, K., Lu, A.X., Mehta, R., Mofrad, M.R.K., Ng, M.Y., Pannu, J., Ré, C., St. John, J., Sullivan, J., Tey, J., Viggiano, B., Zhu, K., Zynda, G., Balsam, D., Collison, P., Costa, A.B., Hernandez-Boussard, T., Ho, E., Liu, M.-Y., McGrath, T., Powell, K., Pinglay, S., Burke, D.P., Goodarzi, H., Hsu, P.D., & Hie, B.L.  (2026). Genome modeling and design across all domains of life with Evo 2. Nature. https://doi.org/10.1038/s41586-026-10176-5

Arc Institute is an independent nonprofit research organization based in Palo Alto, California, that aims to accelerate scientific progress and understand the root causes of complex diseases. Arc's investigators are supported by long-term funding and freedom to pursue bold ideas. Its Technology Centers leverage multi-omics, genome engineering, and cellular, mammalian and computational models to advance discoveries at the intersection of biology and artificial intelligence. Founded in 2021, Arc partners with Stanford, UC Berkeley, and UCSF.

---

Journal

Nature

DOI

10.1038/s41586-026-10176-5 

Method of Research

Computational simulation/modeling

Subject of Research

Not applicable

Article Title

Genome modeling and design across all domains of life with Evo 2

Article Publication Date

4-Mar-2026

COI Statement

Funding information and declarations of interest can be found in the manuscript.